EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and safety of daratumumab in multiresistant immune‐mediated thrombotic thrombocytopenic purpura

Julia Weisinger iD, Raïda Bouzid, Dana Ranta, Pascal Woaye-Hune, Fleur Cohen-Aubart, Clotilde Gaible, Zora Marjanovic iD, Elise Corre, Anne-Christine Joly, Minh-Tam Baylatry, Berangère S Joly, Agnès Veyradier und 1 weitere

British Journal of Haematology · 2024-11 · 205 (5) · 1951-1958

DOI: 10.1111/bjh.19752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 04.09.2024. Verfasst von Julia Weisinger und 12 weiteren Autor:innen. Beteiligte Einrichtung: Service d'hématologie, Centre de Référence des Microangiopathies Thrombotiques (CNR-MAT), Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Pari…. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Antibodies, Monoclonal, ADAMTS13 Protein. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Union, French Ministry of Health (Projet Hospitalier de Recherche Clinique), European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The immunosuppressive treatment of immune‐mediated thrombotic thrombocytopenic purpura (iTTP) in patients with intolerance or refractoriness to the B‐cell depleting monoclonal antibody rituximab remains debated. Daratumumab, a plasma cell‐directed monoclonal antibody targeting CD38, represents a therapeutic option, but data are scarce. The French Thrombotic Microangiopathies Reference Center conducted a nationwide survey on iTTP patients treated with daratumumab. Nine episodes from seven patients were identified. Treatment was administered for A Disintegrin And Metalloproteinase with ThromboSpondin‐1 motifs, 13th member (ADAMTS13) relapses while patients were otherwise in clinical response ( N = 8), or during the acute phase of the disease following rituximab intolerance ( N = 1). Patients have received a median of three previous therapeutic lines. ADAMTS13 activity improved in eight cases following daratumumab administration, including three cases where ADAMTS13 normalized. ADAMTS13 relapses occurred in three patients; in two cases, retreatment with daratumumab was successful. Median ADAMTS13 relapse‐free survival was not reached; 12‐month ADAMTS13 relapse‐free survival was 56%. Daratumumab‐related adverse events occurred in five cases and were non‐severe infusion‐related reactions in all cases. These results suggest that daratumumab may be an effective treatment option for iTTP patients with intolerance or refractoriness to rituximab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombotic ThrombocytopenicAntibodies, MonoclonalADAMTS13 ProteinHumansFemaleMaleMiddle AgedAdultAgedRituximabTreatment Outcome

Stichwörter der Autor:innen

ADAMTS13daratumumabprognosisrelapsethrombotic thrombocytopenic purpura

Substanzen

daratumumabAntibodies, MonoclonalADAMTS13 ProteinADAMTS13 protein, humanRituximab

Autor:innen und Institutionen

  • Service d'hématologie, Centre de Référence des Microangiopathies Thrombotiques (CNR-MAT), Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris and Sorbonne Université (AP-HP.6), Paris, France.
  • INSERM Unité Mixte de Recherche (UMRS) 1138, Centre de Recherche des Cordeliers, Paris, France.
  • Service d'Hématologie, Centre Hospitalier Universitaire de Nancy, Nancy, France.
  • Centre Hospitalier Départemental Vendée, La Roche sur Yon, France.
  • Départment de Médecine Interne 2, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris and Sorbonne Université (AP-HP.6), Paris, France.
  • Néphrologie et Transplantation d'organes, Centre Hospitalier Universitaire Rangueil, Toulouse, France.

ORCID-Profile: Julia Weisinger, Zora Marjanovic, Paul Coppo

Förderung

  • European Union
  • French Ministry of Health (Projet Hospitalier de Recherche Clinique)
  • European Commission

Zitieren

APA

Weisinger, J., Bouzid, R., Ranta, D., Woaye-Hune, P., Cohen-Aubart, F., Gaible, C., Marjanovic, Z., Corre, E., Joly, A. C., Baylatry, M. T., Joly, B. S., Veyradier, A., & Coppo, P. (2024). Efficacy and safety of daratumumab in multiresistant immune‐mediated thrombotic thrombocytopenic purpura. British Journal of Haematology, 205(5), 1951-1958. https://doi.org/10.1111/bjh.19752

Vancouver

Weisinger J, Bouzid R, Ranta D, Woaye-Hune P, Cohen-Aubart F, Gaible C, et al. Efficacy and safety of daratumumab in multiresistant immune‐mediated thrombotic thrombocytopenic purpura. British Journal of Haematology. 2024;205(5):1951-1958. doi:10.1111/bjh.19752

BibTeX
@article{Weisinger2024,
  author = {Weisinger, Julia and Bouzid, Raïda and Ranta, Dana and Woaye-Hune, Pascal and Cohen-Aubart, Fleur and Gaible, Clotilde and Marjanovic, Zora and Corre, Elise and Joly, Anne-Christine and Baylatry, Minh-Tam and Joly, Berangère S and Veyradier, Agnès and Coppo, Paul},
  title = {Efficacy and safety of daratumumab in multiresistant immune‐mediated thrombotic thrombocytopenic purpura},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {205},
  number = {5},
  pages = {1951--1958},
  doi = {10.1111/bjh.19752}
}
Kostenlos starten →